With an siRNA conjugate encapsulated within rHDL-coated particles, Ding et al. demonstrated the utility of this delivery method by targeting an oncogene (VEGF, Pokemon, or BCL-2) with tumor uptake and tumor inhibitory studies [71, 72]. The gene discussed is BCL2; the disease is neoplasm.